The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Sequential Amyloid-β Degradation by the Matrix Metalloproteases MMP-2 and MMP-9
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some MMPs may play an important role in degrading soluble Ab, such as secreted MMP-2 and MMP-9 that generate C-terminally truncated Ab fragments and membrane-type MMP-14 that degrades both soluble and fibrillary Ab.
“Increasing in vitro evidence indicates that some MMPs may play an important role in degrading soluble Ab (sAb), such as secreted MMP-2 and MMP-9 that generate C-terminally truncated Ab fragments and membrane-type MMP-14 that degrades both soluble and fibrillary Ab (29)(30)(31)(32).”
From Differential protective effects of connective tissue growth factor against Aβ neurotoxicity on neurons and glia (2017) · cites this paper as [31]
MT1-MMP, MMP-9 and MMP-2 are close MT5-MMP homologues involved in the control of APP metabolism and amyloidogenesis.
“all close MT5-MMP homologues, also involved in the control of APP metabolism and amyloidogenesis [33, 34, 54, 55]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Yang, Y., Estrada, E. Y., Thompson, J. F., Liu, W., & Rosenberg, G. A. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600375 · Cited by 1,060
Matrix metalloproteinases and their multiple roles in neurodegenerative diseases
Rosenberg, G. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70016-x · Cited by 594
Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380 · cited 2×
“In contrast, MMP-9 has been reported to partially degrade preformed A fibrils (9), generating few identifiable truncated fragments (A (1–20) and A (1–30)) that do not match the sequence of events described in our studies employing soluble A 40 and A 42 homologues.”
BackgroundBackstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331
Tomidokoro, Y., Lashley, T., Rostagno, A., Neubert, T. A., Bojsen-Møller, M., Braendgaard, H., Plant, G., Holton, J., Frangione, B., Révész, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504038200 · Cited by 68
Self-citation
Flagged first, then by citations
Research works printed but not linked: 45
- Sekhon, 2010, Matrix metalloproteinases–an overview, Res. Rep. Biol, 2010, 1
- Sbardella, 2012, Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes, Mol. Aspects Med, 33, 119, 10.1016/j.mam.2011.10.015 · DOI
- Nagase, 2006, Structure and function of matrix metalloproteinases and TIMPs, Cardiovasc. Res, 69, 562, 10.1016/j.cardiores.2005.12.002 · DOI
- Endres, 2012, Regulation of α-secretase ADAM10 expression and activity, Exp. Brain Res, 217, 343, 10.1007/s00221-011-2885-7 · DOI
- Ghiso, 2002, Amyloidosis and Alzheimer's disease, Adv. Drug Deliv. Rev, 54, 1539, 10.1016/S0169-409X(02)00149-7 · DOI
- Vardy, 2005, Proteolytic mechanisms in amyloid-β metabolism: therapeutic implications for Alzheimer's disease, Trends Mol. Med, 11, 464, 10.1016/j.molmed.2005.08.004 · DOI
- Roher, 1994, Proteolysis of Aβ peptide from Alzheimer disease brain by gelatinase A, Biochem. Biophys. Res. Commun, 205, 1755, 10.1006/bbrc.1994.2872 · DOI
- Crouch, 2009, Restored degradation of the Alzheimer's amyloid-β peptide by targeting amyloid formation, J. Neurochem, 108, 1198, 10.1111/j.1471-4159.2009.05870.x · DOI
- Yin, 2006, Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-β peptide catabolism, J. Neurosci, 26, 10939, 10.1523/JNEUROSCI.2085-06.2006 · DOI · Paper page
- Montaner, 2003, Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke, Circulation, 107, 598, 10.1161/01.CIR.0000046451.38849.90 · DOI
- Alvarez-Sabín, 2004, Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome, Stroke, 35, 1316, 10.1161/01.STR.0000126827.69286.90 · DOI
- Abilleira, 2003, Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage, J. Neurosurg, 99, 65, 10.3171/jns.2003.99.1.0065 · DOI
- Hernandez-Guillamon, 2010, Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-β E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells, J. Biol. Chem, 285, 27144, 10.1074/jbc.M110.135228 · DOI
- Hampel, 2010, Biological markers of amyloid β-related mechanisms in Alzheimer's disease, Exp. Neurol, 223, 334, 10.1016/j.expneurol.2009.09.024 · DOI
- Fossati, 2010, Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-β variants in cells composing the cerebral vessel walls, FASEB J, 24, 229, 10.1096/fj.09-139584 · DOI
- Knight, 1992, A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases, FEBS Lett, 296, 263, 10.1016/0014-5793(92)80300-6 · DOI
- Tomidokoro, 2010, Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AβD23N in parenchymal and cerebrovascular amyloid deposits, Am. J. Pathol, 176, 1841, 10.2353/ajpath.2010.090636 · DOI
- Weksler, 2005, Blood-brain barrier-specific properties of a human adult brain endothelial cell line, FASEB J, 19, 1872, 10.1096/fj.04-3458fje · DOI
- Fossati, 2013, Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid β and the Asn23 Iowa mutation, Biochem. J, 456, 347, 10.1042/BJ20130652 · DOI
- Kridel, 2001, Substrate hydrolysis by matrix metalloproteinase-9, J. Biol. Chem, 276, 20572, 10.1074/jbc.M100900200 · DOI
- Chen, 2002, A unique substrate recognition profile for matrix metalloproteinase-2, J. Biol. Chem, 277, 4485, 10.1074/jbc.M109469200 · DOI
- Aureli, 2008, Structural bases for substrate and inhibitor recognition by matrix metalloproteinases, Curr. Med. Chem, 15, 2192, 10.2174/092986708785747490 · DOI
- Obici, 2005, A novel AβPP mutation exclusively associated with cerebral amyloid angiopathy, Ann. Neurol, 58, 639, 10.1002/ana.20571 · DOI
- Rostagno, 2010, Cerebral amyloidosis: amyloid subunits, mutants and phenotypes, Cell. Mol. Life Sci, 67, 581, 10.1007/s00018-009-0182-4 · DOI
- Miners, 2011, Aβ-degrading enzymes: potential for treatment of Alzheimer disease, J. Neuropathol. Exp. Neurol, 70, 944, 10.1097/NEN.0b013e3182345e46 · DOI · Paper page
- Kheterpal, 2006, Structural differences in Aβ amyloid protofibrils and fibrils mapped by hydrogen exchange–mass spectrometry with on-line proteolytic fragmentation, J. Mol. Biol, 361, 785, 10.1016/j.jmb.2006.06.066 · DOI
- McLaurin, 2000, Review: modulating factors in amyloid-β fibril formation, J. Struct. Biol, 130, 259, 10.1006/jsbi.2000.4289 · DOI
- Calero, 2012, Search for amyloid-binding proteins by affinity chromatography, Methods Mol. Biol, 849, 213, 10.1007/978-1-61779-551-0_15 · DOI
- Gorbenko, 2006, The role of lipid-protein interactions in amyloid-type protein fibril formation, Chem. Phys. Lipids, 141, 72, 10.1016/j.chemphyslip.2006.02.006 · DOI
- Portelius, 2008, Targeted proteomics in Alzheimer's disease: focus on amyloid-β, Expert Rev. Proteomics, 5, 225, 10.1586/14789450.5.2.225 · DOI
- Portelius, 2006, Determination of β-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry, J. Proteome Res, 5, 1010, 10.1021/pr050475v · DOI · Paper page
- Ghiso, 2001, Systemic amyloid deposits in Familial British Dementia, J. Biol. Chem, 276, 43909, 10.1074/jbc.M105956200 · DOI
- Bateman, 2006, Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo, Nat. Med, 12, 856, 10.1038/nm1438 · DOI · Paper page
- Morelli, 2002, The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidosis, Neurochem. Res, 27, 1387, 10.1023/A:1021679817756 · DOI
- Wang, 2006, Clearance of amyloid-β in Alzheimer's disease: progress, problems and perspectives, Drug Discov. Today, 11, 931, 10.1016/j.drudis.2006.08.004 · DOI
- Miners, 2008, Aβ-degrading enzymes in Alzheimer's disease, Brain Pathol, 18, 240, 10.1111/j.1750-3639.2008.00132.x · DOI
- Deb, 1996, Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with β-amyloid peptides, J. Neurochem, 66, 1641, 10.1046/j.1471-4159.1996.66041641.x · DOI
- Deb, 2003, β-Amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes, Brain Res, 970, 205, 10.1016/S0006-8993(03)02344-8 · DOI · Paper page
- Lee, 2005, Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage, J. Neurol. Sci, 229, 249, 10.1016/j.jns.2004.11.041 · DOI
- Hernandez-Guillamon, 2012, MMP-2/MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke, Brain Pathol, 22, 133, 10.1111/j.1750-3639.2011.00512.x · DOI
- Rosenberg, 1990, Collagenase-induced intracerebral hemorrhage in rats, Stroke, 21, 801, 10.1161/01.STR.21.5.801 · DOI
- Rosenberg, 1993, Bacterial collagenase disrupts extracellular matrix and opens blood-brain barrier in rat, Neurosci. Lett, 160, 117, 10.1016/0304-3940(93)90927-D · DOI
- Rosenberg, 1995, Tumor necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window, Brain Res, 703, 151, 10.1016/0006-8993(95)01089-0 · DOI
- Rosenberg, 1992, TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase, Brain Res, 576, 203, 10.1016/0006-8993(92)90681-X · DOI
- Liu, 2012, Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage, J. Neurosci, 32, 3044, 10.1523/JNEUROSCI.6409-11.2012 · DOI · Paper page
Cited by
Sorted by citations
Age-associated Physiological and Pathological Changes at the Blood-Brain Barrier: A Review
Erdő, F., Denes, L., & de Lange, E. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16679420 · Cited by 426
Alić, I., Goh, P. A., Murray, A., Portelius, E., Gkanatsiou, E., Gough, G., Mok, K. Y., Koschut, D., Brunmeir, R., Yeap, Y. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0806-5 · Cited by 123
Self-citationMatrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges
Zipfel, P., Rochais, C., Baranger, K., Rivera, S., & Dallemagne, P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00352 · Cited by 94
García-González, L., Pilat, D., Baranger, K., & Rivera, S. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00244 · Cited by 88
Pilat, D., Paumier, J.-M., García-González, L., Louis, L., Stephan, D., Manrique, C., Khrestchatisky, M., Di Pasquale, E., Baranger, K., & Rivera, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02407-z · Cited by 28
Yang, C.-N., Wu, M.-F., Liu, C.-C., Jung, W.-H., Chang, Y.-C., Lee, W.-P., Shiao, Y.-J., Wu, C.-L., Liou, H.-H., Lin, S.-K., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx278 · Cited by 27
Arber, C., Villegas-Llerena, C., Toombs, J., Pocock, J. M., Ryan, N. S., Fox, N. C., Zetterberg, H., Hardy, J., & Wray, S. (2019) · Brain Communications · doi:10.1093/braincomms/fcz024 · Cited by 19
Kamboj, S., Harms, C., Wright, D., Nash, A., Klein-Seetharaman, J., & Sarkar, S. K. (2022) · doi:10.21203/rs.3.rs-1258797/v1 · Cited by 1
Metadata
- Authors
- Hernandez-Guillamon, M., Mawhirt, S., Blais, S., Montaner, J., Neubert, T. A., Rostagno, A., & Ghiso, J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 290
- Issue
- 24
- Pages
- 15078-15091
- ISSN
- 0021-9258
- Cited by
- 137
- References
- 7
- Language
- en
- Licence
- Funders
- National Institutes of Health (AG030539, NS051715, P30 NS050276, U24 CA126485)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
